CD30 Monoclonal Antibody (mCD30.1), PE, eBioscience™, Invitrogen™

Description

• Description: The mCD30.1 monoclonal antibody reacts with mouse CD30, a 105-120 kDa member of the TNFR superfamily
• CD30 is not detectable on splenocytes, but can be upregulated on T cells stimulated in vitro through TCR with a peak expression around day 4-5 post-activation
• CD30 is expressed by both CD8^+ and CD4^+ activated cells
• It is suggested that CD30 regulates cytokine secretion by T cells and has a role in T cell development
• Applications Reported: The mCD30.1 antibody has been reported for use in flow cytometric analysis
• Applications Tested: The mCD30.1 antibody has been tested by flow cytometric analysis of resting and activated mouse splenocytes
• This can be used at less than or equal to 1 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser
• Filtration: 0.2 μm post-manufacturing filtered
• CD30 (Ki-1, TNF Receptor Superfamily Member 8) is a type I transmembrane glycoprotein of the TNF receptor superfamily
• CD30 was originally identified as a cell surface antigen of Hodgkins and Reed-Sternberg cells using monoclonal antibody Ki-1
• The ligand for CD30 is CD30L (CD153)
• The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death
• CD30 has a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas
• CD30 acts as a costimulatory molecule in thymic negative selection
• In addition to its expression on Hodgkin's and Reed-Sternberg cells, CD30 is also found in some non-Hodgkin's lymphomas (including Burkitt's lymphomas), virus-infected T and B cells, and on normal T and B cells after activation
• In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and the IL4 receptor
• Soluble form of CD30 (sCD30) serves as a marker reflecting Th2 immune response
• TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB
• CD30 is a positive regulator of apoptosis, and has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity
• Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported
• CD30 is expressed by mononuclear cells in Hodgkin's lymphoma, Reed Sternberg cells and most Anaplastic Large Cell Lymphomas (ALCL)
• CD30 is also expressed by embryonal carcinomas.